

500



5010

DT Rec'd PCT/PTO

M-F PCT
31 JUL 2002
#6

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

6

Application Number

10/030,014

Filing Date

December 28, 2001

First Named Inventor

Alessandro SETTE

Group Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket No.

399632002100

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Reply☐ After Final☐ Affidavits/declarations☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement;
PTO form 1449; and 21 references☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/
Incomplete Application☐ Response to Missing Parts
under 37 CFR 1.52 or 1.53☐ Assignment Papers
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ After Allowance Communication to
Group☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please identify
below): Return postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm
or
Individual NameIrina E. Britva
Registration No. 50,498

Signature

u. Bp

Date

July 25, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on July 26, 2002

Jose Luna


Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 399632002100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 26, 2002.


Jose Luna

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Alessandro SETTE, et al.

Serial No.: 10/030,014

Filing Date: December 28, 2001

For: HLA BINDING PEPTIDES AND THEIR
USES

Examiner: To be assigned

Group Art Unit: To be assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This application is related to U.S.S.N. 60/141,422 filed June 29, 1999; U.S.S.N. 08/205,713 filed March 4, 1994; U.S.S.N. 09/017,735; U.S.S.N. 08/753,622; U.S.S.N. 08/822,382; U.S.S.N. 60/013,980; U.S.S.N. 08/589,108; U.S.S.N. 08/454,033; U.S.S.N.

08/349,177; U.S.S.N. 08/159,184; U.S.S.N. 08/073,205; and U.S.S.N. 08/027,146. This application is also related to U.S.S.N. 09/017,524; U.S.S.N. 08/821,739; U.S.S.N. 60/013,833; U.S.S.N. 08/758,409; U.S.S.N. 08/589,107; U.S.S.N. 08/451,913 and to U.S.S.N. 08/347,610; U.S.S.N. 08/186,266; U.S.S.N. 08/159,339; U.S.S.N. 09/116,061; U.S.S.N. 08/103,396; U.S.S.N. 08/027,746; and U.S.S.N. 07/926,666. This application is also related to U.S.S.N. 09/017,743; U.S.S.N. 08/753,615; U.S.S.N. 08/590,298; U.S.S.N. 08/452,843; U.S.S.N. 09/115,400; U.S.S.N. 08/344,824; and U.S.S.N. 08/278,634. This application is also related to U.S.S.N. 08/197,484 and U.S.S.N. 08/815,396.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 399632002100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 25, 2002

Respectfully submitted,

By: _____

U. Britva

Irina E. Britva
Registration No. 50,498

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5175
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 399632002100	Application Number 10/030,014
	Applicant Alessandro SETTE, et al.	
	Filing Date December 28, 2001	Group Art Unit To Be Assigned
	Mailing Date July <u>26</u> 2002	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	1.	Barber et al. "Overlap in the Repertoires of Peptides Bound In Vivo by a Group of Related Class I HLA-B Allotypes" Curr. Biol. 5:179-190 (1995)
	2.	Bjorkman et al. "Structure of the Human Class I Histocompatibility Antigen, HLA-A2" Nature 329:506-512 (1987)
	3.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science 242:1045-1047 (1988)
	4.	DiBrino et al. "Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8" J. Immunol. 152:620-631 (1994)
	5.	De Bruijn et al. "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses" Eur. J. Immunol. 21:2963-2970 (1991)
	6.	Falk et al. "Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules" Nature 351:290-296 (1991)
	7.	Hill et al. "Molecular Analysis of the Association of HLA-B53 and Resistance to Severe Malaria" Nature 360:434-439 (1992)
	8.	Hunt et al. "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry" Science 225:1261-1263 (1992)
	9.	Jardetzky et al. "Identification of Self Peptides Bound to Purified HLA-B27" Nature 353:326-329 (1991)
	10.	Kondo et al. "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules" J. Immunol. 155:4307-4312 (1995)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 399632002100	Application Number 10/030,014
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Alessandro SETTE, et al.	
		Filing Date December 28, 2001	Group Art Unit To Be Assigned
		Mailing Date July __, 2002	
			
	11.	Kondo et al. "Two Distinct HLA-A*0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes" Immunogenetics 45:249-258 (1997)	
	12.	Kubo et al. "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles" J. Immunol. 152:3913-3924 (1994)	
	13. (Pamer et al. "Precise Prediction of a Dominant Class I MHC-Restricted Epitope of Listeria Monocytogenes" Nature 353:852-855 (1991)	
	14.	Rammensee et al. "MHC Ligands and Peptide Motifs: First Listing" Immunogenetics 41:178-228 (1995)	
	15.	Ruppert et al. "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules" Cell 74:929-937 (1993)	
	16.	Schaeffer et al. "Relative Contribution of "Determinant Selection" and "Holes in the T-Cell Repertoire" to T-Cell Responses" Proc. Natl. Acad. Sci. USA 86:4649-4653 (1989)	
	17.	Sette et al. "Prediction of Major Histocompatibility Complex Binding Regions of Protein Antigens by Sequence Pattern Analysis" Proc. Natl. Acad. Sci. USA 86:3296-3300 (1989)	
	18.	Sette et al. "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes" J. Immunol. 153:5586-5592 (1994)	
	19.	Sidney et al. "Several HLA Alleles Share Overlapping Peptide Specificities" J. Immunol. 154:247-259 (1995)	
	20.	Sidney et al. "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules" Hum. Immunol. 45:79-93 (1996)	
	21.	Zhang et al. "An HLA-A11-Specific Motif in Nonamer Peptides Derived from Viral and Cellular Proteins" Proc. Natl. Acad. Sci. USA 90:2217-2221 (1993)	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			